Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
THAR 
Tharimmune Inc. (THAR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: THAR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.77% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.38M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 1.59 | 52 Weeks Range 0.95 - 9.08 | Updated Date 09/15/2025 |
52 Weeks Range 0.95 - 9.08 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -140.33% | Return on Equity (TTM) -340.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14764160 | Price to Sales(TTM) - |
Enterprise Value 14764160 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.32 | Shares Outstanding 5336440 | Shares Floating 3653088 |
Shares Outstanding 5336440 | Shares Floating 3653088 | ||
Percent Insiders 17.13 | Percent Institutions 1.5 |
Upturn AI SWOT
Tharimmune Inc.
Company Overview
History and Background
Tharimmune, Inc., formerly known as Immunovative Therapies, Ltd., is a clinical-stage biotechnology company focused on developing a pipeline of therapeutic candidates for unmet medical needs. It was founded in 2011. In December 2023, the company completed a reverse merger with Maxim Merger Sub, Inc. and changed its name to Tharimmune, Inc.
Core Business Areas
- TH104: TH104 is Tharimmune's lead drug candidate. It is an oral therapeutic in clinical development designed to address a range of inflammatory conditions, including acute decompensation of chronic liver failure (AD-CLIF).
- Other Indications: Tharimmune is exploring TH104's potential in other inflammatory diseases and exploring other theraupeutic candidates.
Leadership and Structure
Dr. Raju Mohan is the Chief Executive Officer. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- TH104: TH104 is the primary asset. It is currently in clinical trials. Market share data is not currently available due to its stage of development. Competitors in the inflammatory disease space include companies developing treatments for specific inflammatory conditions. This includes major pharmaceutical companies and other biotech firms specializing in inflammatory pathways.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The market for inflammatory disease treatments is substantial and growing.
Positioning
Tharimmune is positioned as a clinical-stage company focused on novel oral therapies for inflammatory diseases. Its competitive advantage lies in its TH104 mechanism of action. They are a small biotech company.
Total Addressable Market (TAM)
The TAM for inflammatory disease treatments is significant, potentially billions of dollars. Tharimmune's positioning within this TAM depends on the successful development and commercialization of its pipeline assets.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (TH104)
- Oral drug formulation
- Experienced management team
Weaknesses
- Early stage of development
- Limited financial resources
- Reliance on single lead product
Opportunities
- Positive clinical trial results
- Partnerships and collaborations
- Expansion into new indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Financial constraints
- Patent Challenges
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- PFE
- BMY
Competitive Landscape
Tharimmune faces significant competition from established pharmaceutical companies with larger resources and approved therapies. Their advantage relies on the novelty of their approach and potential for differentiated efficacy or safety profile.
Growth Trajectory and Initiatives
Historical Growth: No historical revenue growth to analyze.
Future Projections: Future growth is dependent on the successful development and commercialization of TH104 and other pipeline assets.
Recent Initiatives: Focus on advancing TH104 through clinical trials.
Summary
Tharimmune is a high-risk, high-reward clinical-stage biotech company. Its success hinges on the successful development of TH104. The company needs to carefully manage its cash burn and secure additional funding. Positive clinical trial results are crucial for the company's future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party Financial Data Providers
- Press Releases
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Data may be delayed or inaccurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tharimmune Inc.
Exchange NASDAQ | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2022-01-12 | CEO & Director Mr. Sireesh Appajosyula Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.tharimmune.com |
Full time employees 2 | Website https://www.tharimmune.com | ||
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.